Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration

Ophthalmology

Volumn 122, Issue 3, 2015, Pages 579-588

  Csaky, Karl G ^a   Dugel, Pravin U ^b   Pierce, Amy J ^c   Fries, Michael A ^c   Kelly, Deborah S ^c   Danis, Ronald P ^d   Wurzelmann, John I ^c   Xu, Chun Fang ^c   Hossain, Mohammad ^c   Trivedi, Trupti ^c  

^a RETINA FOUNDATION OF THE SOUTHWEST   (United States)

^b RETINAL CONSULTANTS OF ARIZONA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; EYE DROPS; MONOCLONAL ANTIBODY; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR PROTEIN; VASCULOTROPIN RECEPTOR;

ACUTE KIDNEY FAILURE; AGE RELATED MACULAR DEGENERATION; AGED; APPLICATION SITE PAIN; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRAIN HEMORRHAGE; CLINICAL EVALUATION; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ENDOPHTHALMITIS; EYE PAIN; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE BLEEDING; INTESTINE CANCER; INTESTINE PERFORATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYASTHENIA GRAVIS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; RETINAL THICKNESS; RHINOPHARYNGITIS; STEADY STATE; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; URINARY TRACT INFECTION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; NEOPLASM PROTEINS; OPHTHALMIC SOLUTIONS; PHARMACOGENETICS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84924046257     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.09.036     Document Type: Article

References (28)

1. J.W. Miller Age-related macular degeneration revisited-piecing the puzzle: the LXIX Edward Jackson memorial lecture Am J Ophthalmol 155 2013 1 35.e13
2. S.L. Fine, J.W. Berger, M.G. Maguire, and A.C. Ho Age-related macular degeneration N Engl J Med 342 2000 483 492
3. M.A. Zarbin Current concepts in the pathogenesis of age-related macular degeneration Arch Ophthalmol 122 2004 598 614
4. N. Ferrara, L. Damico, and N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
5. M. Hanout, D. Ferraz, and M. Ansari Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development BioMed Res Int 2013 2013 830837
6. D.M. Brown, M. Michels, and P.K. Kaiser Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 2009 57 65.e5
7. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
8. Comparison of Age-related Macular Degeneration Treatments Trials Research Group D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
9. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N Engl J Med 358 2008 2606 2617
10. J.A. Haller Current anti-vascular endothelial growth factor dosing regimens: benefits and burden Ophthalmology 120 5 suppl 2013 S3 S7
11. R. Kumar, V.B. Knick, and S.K. Rudolph Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Ther 6 2007 2012 2021
12. K. Takahashi, Y. Saishin, and Y. Saishin Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib Arch Ophthalmol 127 2009 494 499
13. Y. Yafai, X.M. Yang, and M. Niemeyer Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats Eur J Pharmacol 666 2011 12 18
14. R. Danis, M.M. McLaughlin, and M. Tolentino Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration Br J Ophthalmol 98 2014 172 178
15. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
16. F.G. Holz, W. Amoaku, and J. Donate Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study Ophthalmology 118 2011 663 671
17. A.C. Ho, H. Yue, and L. Wilson Ranibizumab in Wet Age-Related Macular Degeneration (AMD): crossover/rollover patient results in PIER study Invest Ophthalmol Vis Sci 49 2008 E-Abstract 268
18. K.G. Csaky, E.A. Richman, and F.L. Ferris 3rd Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium Invest Ophthalmol Vis Sci 49 2008 479 489
19. I.S. Investigators, U. Chakravarthy, and S.P. Harding Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
20. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
21. A.O. Edwards, R. Ritter 3rd, and K.J. Abel Complement factor H polymorphism and age-related macular degeneration Science 308 2005 421 424
22. R.J. Klein, C. Zeiss, and E.Y. Chew Complement factor H polymorphism in age-related macular degeneration Science 308 2005 385 389
23. M.A. Brantley Jr., A.M. Fang, and J.M. King Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 2007 2168 2173
24. H. Chen, K.D. Yu, and G.Z. Xu Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis PloS One 7 2012 e42464
25. A.Y. Lee, A.K. Raya, and S.M. Kymes Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 93 2009 610 613
26. D. Smailhodzic, P.S. Muether, and J. Chen Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration Ophthalmology 119 2012 2304 2311
27. S.A. Hagstrom, G.S. Ying, and G.J. Pauer Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT) Ophthalmology 120 2013 593 599
28. C.R. Group, D.F. Martin, and M.G. Maguire Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908